(Boursier.com) — Moderna , the American laboratory, indicated on Monday that it now expects to record sales of around 18.5 billion dollars in 2022 thanks to contracts for its Covid-19 vaccine, and around 3.5 billion dollars in additional purchases. potentials, taking into account the updated potential recall candidates for the variants. Moderna also says it is in active discussions for other contracts this year. The pharmaceutical group is also developing a booster vaccine, called mRNA-1273.529, which targets the Omicron variant. Clinical trials are expected to begin shortly. Booster doses of the current vaccine, mRNA-1273, meanwhile, boost levels of neutralizing antibodies against Omicron at dose levels of 50 micrograms and 100 micrograms, Moderna argues.